Nuformix PLC - Collaboration with SGSC

26th June 2018, 07:00

RNS Number : 5743S
Nuformix PLC
26 June 2018
 

 

 

 

Nuformix Plc

("Nuformix" or "the Company")

 

Collaboration with St George Street Capital

 

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has entered into an initial collaboration with St George Street Capital ('SGSC').

 

Under the terms of the agreement SGSC and Nuformix will collaborate to generate new IP to support near-term SGSC clinical trials. If successful, SGSC and Nuformix will extend the collaboration across further SGSC clinical programmes where appropriate.

 

Dr Dan Gooding, CEO, Nuformix plc, said: "St George Street Capital shares core objectives with Nuformix - those of rapidly unlocking the therapeutic potential of various known drugs to transform patient lives. The conclusion of this Agreement allows Nuformix to consider new options which have the potential to in build out its collaborative pipeline.

 

"Whilst focussing on making significant strides forward in its lead programmes, collaborative programmes allow Nuformix to create additional value with reduced risk. In this first collaborative announcement, we're delighted to support St George Street Capital from its inception as we both seek to address previously underserved patient populations with innovative treatments."

 

Mike Johnson, Managing Director of SGS said: "I am delighted to announce the progress we have made in such a short time - we will work collaboratively with those organisations that apply bold new thinking and lateral approaches to help get treatments as quickly as possible to the people who need them. Nuformix is one of those companies that we believe will be instrumental in helping us accelerate treatments to patients"

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

Enquiries:

Nuformix Plc

Dan Gooding, CEO

 

+44 (0) 1223 423667

Gable Communications Limited

John Bick / Justine James

+44 (0) 20 7193 7463

 

 

 

About Nuformix plc

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

 

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

 

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

 

About St George Street Capital

Established in 2018, St George Street Capital is a new type of charity, sourcing investment to fast-track clinical trials to get new treatments as quickly as possible to the people that need them. Thousands of treatments with powerful potential are currently stalled in development, keeping patients suffering needlessly. Our mission is to apply bold new thinking and lateral approaches to unlock all this therapeutic potential and transform the lives of patients and their families.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCQQLBLVQFEBBL ]]>

Companies mentioned in this announcement